These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37131014)

  • 1. The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study.
    Serageldin MA; Kassem AB; El-Kerm Y; Helmy MW; El-Mas MM; El-Bassiouny NA
    Drug Saf; 2023 Jun; 46(6):587-599. PubMed ID: 37131014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
    Gadisa DA; Assefa M; Wang SH; Yimer G
    J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
    Nanni O; Amadori D; De Censi A; Rocca A; Freschi A; Bologna A; Gianni L; Rosetti F; Amaducci L; Cavanna L; Foca F; Sarti S; Serra P; Valmorri L; Bruzzi P; Corradengo D; Gennari A;
    Breast Cancer Res Treat; 2019 Apr; 174(2):433-442. PubMed ID: 30536182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
    Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
    Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
    Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
    Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
    Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
    Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
    Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial.
    Bakry HM; Mansour NO; ElKhodary TR; Soliman MM
    Front Pharmacol; 2023; 14():1181312. PubMed ID: 37583905
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
    Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study.
    Serageldin MA; El-Bassiouny NA; El-Kerm Y; Aly RG; Helmy MW; El-Mas MM; Kassem AB
    Br J Clin Pharmacol; 2024 Aug; ():. PubMed ID: 39113190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
    McArthur HL; Rugo H; Nulsen B; Hawks L; Grothusen J; Melisko M; Moasser M; Paulson M; Traina T; Patil S; Zhou Q; Steingart R; Dang C; Morrow M; Cordeiro P; Fornier M; Park J; Seidman A; Lake D; Gilewski T; Theodoulou M; Modi S; D'Andrea G; Sklarin N; Robson M; Moynahan ME; Sugarman S; Sealey JE; Laragh JH; Merali C; Norton L; Hudis CA; Dickler MN
    Clin Cancer Res; 2011 May; 17(10):3398-407. PubMed ID: 21350003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
    Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE; Swain SM; Mamounas EP; Wolmark N
    Breast Cancer Res Treat; 2015 Jan; 149(1):163-9. PubMed ID: 25542269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.